Ultragenyx Pharmaceutical, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90400D1081
USD
26.13
0.2 (0.77%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
136.00
207.00
159.93
166.50
139.29
164.88
139.49
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
136.00
207.00
159.93
166.50
139.29
164.88
139.49
Raw Material Cost
38.00
37.78
36.60
31.62
37.65
25.97
29.78
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
21.00
19.00
14.15
14.04
14.34
15.52
15.71
Selling and Distribution Expenses
88.00
89.00
86.62
86.65
87.80
82.50
80.35
Other Expenses
15.80
17.52
19.35
14.21
14.24
16.32
14.56
Total Expenditure (Excl Depreciation)
305.00
321.00
330.82
274.38
282.23
287.16
271.48
Operating Profit (PBDIT) excl Other Income
-169
-114
-170.9
-107.89999999999999
-142.89999999999998
-122.30000000000001
-132
Other Income
6.00
5.00
4.82
7.93
7.67
5.94
13.81
Operating Profit (PBDIT)
-155.00
-100.22
-157.46
-91.34
-126.28
-107.25
-109.42
Interest
21.00
19.00
14.15
14.04
14.34
15.52
15.71
Exceptional Items
0.00
0.00
0.68
-0.01
-0.16
-1.55
0.68
Gross Profit (PBDT)
98.00
169.22
123.34
134.88
101.64
138.90
109.72
Depreciation
8.00
8.79
8.61
8.62
8.99
9.08
8.76
Profit Before Tax
-184.00
-128.00
-179.54
-114.00
-149.77
-133.40
-133.21
Tax
1.00
1.00
0.87
0.95
1.31
-0.02
0.30
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-185.00
-129.00
-180.41
-114.95
-151.08
-133.38
-133.52
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
-185.00
-129.00
-180.41
-114.95
-151.08
-133.38
-133.52
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-185.00
-129.00
-180.41
-114.95
-151.08
-133.38
-133.52
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
-236.00
-80.00
9.16
151.29
144.25
255.30
346.83
Earnings per share (EPS)
-1.84
-1.29
-1.81
-1.17
-1.57
-1.39
-1.4
Diluted Earnings per share
-1.84
-1.29
-1.81
-1.17
-1.57
-1.39
-1.4
Operating Profit Margin (Excl OI)
-124.26%
-55.07%
-106.85%
-64.8%
-102.62%
-74.16%
-94.62%
Gross Profit Margin
-129.41%
-57.59%
-106.88%
-63.3%
-101.07%
-75.4%
-89.22%
PAT Margin
-136.03%
-62.32%
-112.81%
-69.04%
-108.46%
-80.9%
-95.71%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is -34.30% vs 29.46% in Dec 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is -43.41% vs 28.49% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is -53.04% vs 35.18% in Dec 2025

stock-summary

Interest

QoQ Growth in quarter ended Mar 2026 is 10.53% vs 34.75% in Dec 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

Compare Quarterly Results Of Ultragenyx Pharmaceutical, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
136.00
0.00
136.00
Other Operating Income
0.00
0.00
0.00
Total Operating income
136.00
0.00
136.00
Raw Material Cost
38.00
0.00
38.00
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
21.00
1.09
19.91
1,826.61%
Selling and Distribution Expenses
88.00
11.35
76.65
675.33%
Other Expenses
15.80
7.78
8.02
103.08%
Total Expenditure (Excl Depreciation)
305.00
90.24
214.76
237.99%
Operating Profit (PBDIT) excl Other Income
-169.00
-90.24
-78.76
-87.28%
Other Income
6.00
11.32
-5.32
-47.00%
Operating Profit (PBDIT)
-155.00
-78.92
-76.08
-96.40%
Interest
21.00
1.09
19.91
1,826.61%
Exceptional Items
0.00
-1.56
1.56
100.00%
Gross Profit (PBDT)
98.00
0.00
98.00
Depreciation
8.00
0.00
8.00
Profit Before Tax
-184.00
-81.57
-102.43
-125.57%
Tax
1.00
0.00
1.00
Provisions and contingencies
0
0
0.00
Profit After Tax
-185.00
-81.57
-103.43
-126.80%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
-185.00
-81.57
-103.43
-126.80%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-185.00
-81.57
-103.43
-126.80%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
-236.00
957.64
-1,193.64
-124.64%
Earnings per share (EPS)
-1.84
-0.99
-0.85
-85.86%
Diluted Earnings per share
-1.84
-0.99
-0.85
-85.86%
Operating Profit Margin (Excl OI)
-124.26%
0.00%
0.00
-124.26%
Gross Profit Margin
-129.41%
0.00%
0.00
-129.41%
PAT Margin
-136.03%
0.00%
0.00
-136.03%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 13.60 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -34.30% vs 29.46% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -2.37% vs 28.03% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit -18.50 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -43.41% vs 28.49% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -22.44% vs 11.48% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -16.10 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -53.04% vs 35.18% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -20.24% vs 14.44% in Mar 2025

Quarterly - Interest
Interest 2.10 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 10.53% vs 34.75% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 46.85% vs -9.49% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -124.26%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025